PET measurement of tumor metabolism: Jhaveri and Linden provide an overview of the current status of 18F-FDG PET in early treatment response and the promise for routine clinical use as an integrated biomarker in cancer therapies.
Page 1
DOTATOC uptake in meningioma and glioma: Collamati and colleagues report on 90Y-DOTATOC uptake in meningiomas and high-grade gliomas as part of development of a novel radioguided surgery technique for cerebral tumors using β− radiation.
Page 3
18F-FET PET in high-grade astrocytomas: Jansen and colleagues investigate the value of dynamic 18F-FET PET in providing prognostic information at primary diagnosis in patients with astrocytic high-grade gliomas.
Page 9
Tracer uptake in OSCC inflammation: Kim and colleagues demonstrate the effects of intratumoral inflammation on 18F-FDG uptake in oral squamous cell carcinoma and assess the ability of associated parameters to predict tumor progression.
Page 16
Pre-RT PET in OSCC: Kang and colleagues research the impact of an additional PET/CT scan before adjuvant radiotherapy or concurrent chemoradiotherapy on disease-free and disease-specific survival in patients with oral squamous cell carcinoma.
Page 22
PET as cancer biomarker: Connolly and colleagues assess changes in maximum standardized uptake values corrected for lean body mass on 18F-FDG PET as predictors of pathologic complete response to chemotherapy in human epidermal growth factor receptor 2–negative breast cancer.
Page 31
18F-FDG PET heterogeneity and volume: Hatt and colleagues explore in patients with various cancers the potential of heterogeneity quantification by textural features for providing valuable clinical information in addition to functional volume.
Page 38
TLG and NSCLC: Park and colleagues detail the prognostic value of various 18F-FDG PET/CT metabolic indices, including total lesion glycolysis, in surgically resected stage IA non–small cell lung cancer.
Page 45
Estrogen receptor imaging in ovarian cancer: van Kruchten and colleagues evaluate the feasibility of 18F-FES PET to noninvasively determine tumor estrogen receptor α expression status in patients with epithelial ovarian cancer.
Page 50
62Cu-ETS PET and tumor perfusion: Fletcher and colleagues describe whole-body 62Cu-ETS PET/CT tumor perfusion imaging in patients with metastatic renal carcinoma and compare the performance of this tracer as a quantitative tumor perfusion marker with that of 15O-water.
Page 56
89Zr-bevacizumab PET in RCC: Oosting and colleagues determine the tumor uptake of this vascular endothelial growth factor A–binding PET tracer in patients with metastatic renal cell carcinoma before and during antiangiogenic treatment.
Page 63
Perspectives on DOTATATE PET/CT: Herrmann and colleagues report on referring physicians’ perceptions of the impact of somatostatin receptor imaging with 68Ga-DOTATATE PET/CT on management of patients with neuroendocrine tumors.
Page 70
PET and pulmonary iNOS: Huang and colleagues evaluate the ability of 18F-NOS PET/CT to quantify inducible nitric oxide synthase expression from endotoxin-induced lung inflammation in healthy volunteers.
Page 76
Inhibiting P-gp at the BBB: Kreisl and colleagues examine 2 permeability-glycoprotein inhibitors (tariquidar and disulfiram) and 2 routes of administration to increase brain uptake of 11C-desmethyl-loperamide while avoiding side effects associated with high doses of tariquidar.
Page 82
18F-FET PET in pediatric brain tumors: Dunkl and colleagues report on experience with and diagnostic accuracy of 18F-FET PET imaging in children and adolescents with brain tumors and discuss potential benefits for clinical decision making.
Page 88
Improved MR-based attenuation correction: Burger and colleagues introduce an algorithm modifying Dixon-based MR imaging datasets for attenuation correction in hybrid PET/MR imaging with a multiacquisition variable resonance image combination sequence to reduce metal artifacts.
Page 93
TOF PET update: Surti provides an educational overview of technical innovations and clinical applications in time-of-flight PET.
Page 98
High- and low-specific-activity 18F-DOPA: Kuik and colleagues perform a direct comparison of high- and low-specific-activity 18F-DOPA in a neuroendocrine tumor model to determine whether observed differences have implications for the biologic behavior and imaging properties of the tracer.
Page 106
CCK2R radioimaging: Wayua and Low synthesize a nonpeptidic ligand of cholecystokinin 2 receptor and examine its specificity for CCK2R in vitro and in vivo, with a goal of reducing normal organ retention of CCK2R–targeted drugs.
Page 113
Amyloid SPECT with DRM106: Chen and colleagues investigate 123/125I-DRM106, a compound with sufficient affinity for synthesis of human amyloid-β peptide fibrils and satisfactory metabolic stability, as a SPECT ligand in living brains.
Page 120
PET and pulmonary fibrosis: Bondue and colleagues explore the ability of 18F-FDG and 18F-FBEM–labeled leukocyte PET/CT to monitor metabolic activity and leukocyte recruitment in a mouse model of pulmonary fibrosis.
Page 127
Novel D2/3 receptor agonist: Shalgunov and colleagues detail the synthesis and in vitro and in vivo small-animal assessment of a dopamine D2/3 receptor agonist ligand for PET, with potential for imaging of synaptic transmission.
Page 133
PSMA-targeted photoimmunotherapy: Watanabe and colleagues compare the effectiveness of small and bivalent antibody fragments (including anti–prostate-specific membrane antigen diabody and minibody) with intact immunoglobulin G as photoimmunotherapy agents.
Page 140
Quantitative scanner characterization: Sunderland and Christian review results and data from the SNMMI Clinical Trials Network scanner validation experience, aimed at quantifying and minimizing PET/CT imaging variability across cancer clinical trials.
Page 145
PET and WAT browning: Park and colleagues investigate in mice the potential of 18F-FDG uptake as an imaging biomarker to monitor the process of white adipose tissue browning.
Page 153
Non–fission reactor–produced 99Mo: Pillai and colleagues discuss the advantages of producing 99mTc from non–fission reactor–produced low-specific-activity 99Mo, a model with potential for use in U.S. research reactors to supply domestic 99Mo needs.
Page 159
- © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.